TY - CHAP M1 - Book, Section TI - Chapter 6. Anticoagulation/Venous Thromboembolism A1 - Guffey, William Joshua A1 - Phillips, Beth Bryles A2 - Sutton, S. Scott PY - 2011 T2 - McGraw-Hill's NAPLEX® Review Guide AB - Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in the United States. Each year approximately 2 million people develop VTE and 60,000 of these are fatal.1 The economic burden to the health-care system is roughly $1.5 billion/year.2 VTE encompasses both deep venous thrombosis (DVT) and pulmonary embolism (PE). The mainstay of treatment for VTE is anticoagulant agents. Anticoagulants are also used short and long term to prevent thromboembolic events, including those associated with cardiac valve replacement and myocardial infarction, thromboembolic stroke related to atrial fibrillation, high-risk hospitalized patients, and high-risk patients undergoing surgery. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=7250490 ER -